IDeate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients (pts) with recurrent or metastatic solid tumors.
Authors: Takahiro Kogawa, Seiichiro Mitani, David Berz, Diego Reis, Cindy Li, Tatiane Cristine Ishida, Keyi Wang, Kristi Schmidt, Shigehiro Koganemaru